In the latest quarter, 10 analysts provided ratings for Eastman Chemical (NYSE:EMN), showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 1 | 7 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 1 | 0 | 0 |
| 2M Ago | 0 | 0 | 1 | 0 | 0 |
| 3M Ago | 0 | 1 | 5 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $111.0, a high estimate of $125.00, and a low estimate of $102.00. Highlighting a 1.77% decrease, the current average has fallen from the previous average price target of $113.00.
Decoding Analyst Ratings: A Detailed Look
A clear picture of Eastman Chemical's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Joshua Spector | UBS | Lowers | Buy | $123.00 | $124.00 |
| Steve Byrne | B of A Securities | Lowers | Buy | $109.00 | $115.00 |
| Charles Neivert | Piper Sandler | Lowers | Neutral | $102.00 | $105.00 |
| Patrick Cunningham | Citigroup | Lowers | Neutral | $104.00 | $118.00 |
| John Roberts | Mizuho | Raises | Neutral | $117.00 | $113.00 |
| Michael Sison | Wells Fargo | Raises | Overweight | $125.00 | $110.00 |
| Arun Viswanathan | RBC Capital | Maintains | Sector Perform | $105.00 | $105.00 |
| Arun Viswanathan | RBC Capital | Lowers | Sector Perform | $105.00 | $107.00 |
| David Begleiter | Deutsche Bank | Lowers | Hold | $110.00 | $115.00 |
| Michael Sison | Wells Fargo | Lowers | Equal-Weight | $110.00 | $118.00 |
Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Eastman Chemical. This information provides a snapshot of how analysts perceive the current state of the company. Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Eastman Chemical compared to the broader market. Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Eastman Chemical's stock. This comparison reveals trends in analysts' expectations over time.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Eastman Chemical's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Eastman Chemical analyst ratings.
All You Need to Know About Eastman Chemical
Established in 1920 to produce chemicals for Eastman Kodak, Eastman Chemical has grown into a global specialty chemical company with manufacturing sites around the world. The company generates the majority of its sales outside of the United States, with a strong presence in Asian markets. During the past several years, Eastman has sold noncore businesses, choosing to focus on higher-margin specialty product offerings.
Eastman Chemical's Financial Performance
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Positive Revenue Trend: Examining Eastman Chemical's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 8.69% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Materials sector.
Net Margin: Eastman Chemical's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 7.31% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Eastman Chemical's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.19%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Eastman Chemical's ROA stands out, surpassing industry averages. With an impressive ROA of 1.2%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Eastman Chemical's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.89.
What Are Analyst Ratings?
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Latest Ratings for EMN
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 2022 | Piper Sandler | Maintains | Neutral | |
| Jan 2022 | Barclays | Maintains | Equal-Weight | |
| Jan 2022 | Morgan Stanley | Maintains | Overweight |
View More Analyst Ratings for EMN
View the Latest Analyst Ratings
© 2025 Benzinga.com. Benzinga does not provideinvestment advice All rights reserved.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
